Prospective Evaluation Of FDG PET/CT As A Predictor Of Prognosis In Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

被引：0
|
作者：
Nanni, C. [1 ]
Zamagni, E. [1 ]
Versari, A. [2 ]
Chauvie, S. [3 ]
Tacchetti, P. [1 ]
Pantani, L. [1 ]
Bianchi, A. [3 ]
Rensi, M. [4 ]
Bello, M. [5 ]
Gallamini, A. [6 ]
Patriarca, F. [1 ]
Bertone, E. [3 ]
Zannetti, B. [1 ]
Boccadoro, M. [7 ]
Cavo, M. [1 ]
Fanti, S. [1 ]
机构：
[1] AOU S Orsola Malpighi, Bologna, Italy
[2] Santa Maria Nuova Hosp, IRCSS, Reggio Emilia, Italy
[3] Santa Croce & Carle Hosp, Cuneo, Italy
[4] AOU S Maria Misericordia, Udine, Italy
[5] AO Citta Salute & Sci, Turin, Italy
[6] Lacassagne Canc Ctr, Res & Innovat Dept, Nice, France
[7] Univ Torino, Turin, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-243
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [41] Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.
    Aljama, Mohammed A.
    Sidiqi, M. Hasib
    Kumar, Shaji
    Kourelis, Taxiarchis
    Gertz, Morie A.
    Rajkumar, S. Vincent
    Gonsalves, Wilson I.
    Lacy, Martha
    Buadi, Francis
    Kapoor, Prashant
    Dispenzieri, Angela
    Dingli, David
    Leung, Nelson
    Lust, John Anthony
    Hayman, Suzanne R.
    Go, Ronald S.
    Hwa, Lisa
    Kyle, Robert A.
    Warsame, Rahma M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Comparison of [18F]fluciclovine and [18F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
    Caroline Stokke
    Jakob Nordberg Nørgaard
    Hilde Feiring Phillips
    Alexander Sherwani
    Syed Nuruddin
    James Connelly
    Fredrik Schjesvold
    Mona-Elisabeth Revheim
    Molecular Imaging and Biology, 2022, 24 : 842 - 851
  • [43] FDG PET/CT in multiple myeloma patients: Is it prognostic?
    Nanni, Cristina
    Zamagni, Elena
    Caroli, Paola
    Lopci, Egesta
    Ambrosini, Valentina
    Perrone, Giulia
    Zanetti, Beatrice
    Brioli, Anna Maria
    Fanti, Stefano
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [44] Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
    Shah, Vallari
    Sherborne, Amy L.
    Johnson, David C.
    Ellis, Sidra
    Price, Amy
    Chowdhury, Farzana
    Kendall, Jack
    Jenner, Matthew W.
    Drayson, Mark T.
    Owen, Roger G.
    Gregory, Walter M.
    Morgan, Gareth J.
    Davies, Faith E.
    Cook, Gordon
    Cairns, David A.
    Houlston, Richard S.
    Jackson, Graham
    Kaiser, Martin F.
    LEUKEMIA, 2020, 34 (11) : 3091 - 3096
  • [45] Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
    Vallari Shah
    Amy L. Sherborne
    David C. Johnson
    Sidra Ellis
    Amy Price
    Farzana Chowdhury
    Jack Kendall
    Matthew W. Jenner
    Mark T. Drayson
    Roger G. Owen
    Walter M. Gregory
    Gareth J. Morgan
    Faith E. Davies
    Gordon Cook
    David A. Cairns
    Richard S. Houlston
    Graham Jackson
    Martin F. Kaiser
    Leukemia, 2020, 34 : 3091 - 3096
  • [46] SURVIVAL ANALYSIS OF NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS ENROLLED IN THE RANDOMIZED FORTE TRIAL
    Mina, R.
    Rocchi, S.
    Petrucci, M. T.
    Ledda, A.
    Palmas, A.
    Gentile, M.
    Monaco, F.
    Annibali, O.
    Galieni, P.
    Villanova, T.
    Capra, A.
    Curci, P.
    Pescosta, N.
    Pisani, F.
    Tosi, P.
    Pascarella, A.
    Ballanti, S.
    Grasso, M.
    Corradini, P.
    Musto, P.
    Boccadoro, M.
    Gay, F.
    HAEMATOLOGICA, 2021, 106 (10) : 13 - 14
  • [47] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
    Tsukada, Nobuhiro
    Ikeda, Masahiro
    Shingaki, Sumito
    Miyazaki, Kanji
    Meshitsuka, Sosuke
    Abe, Yu
    Yoshiki, Yumiko
    Suzuki, Kenshi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
  • [48] Predictors of Unsustained Measurable Residual Disease Negativity in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
    Li, Xiaozhe
    Li, Juan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S140 - S140
  • [49] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Figueiredo, Amarilis
    Atkins, Harold
    Mallick, Ranjeeta
    Kekre, Natasha
    Kew, Andrea
    McCurdy, Arleigh
    BLOOD, 2016, 128 (22)
  • [50] MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial
    Zamagni, Elena
    Nanni, Cristina
    Gay, Francesca
    Dozza, Luca
    Scalabrini, Delia Rota
    Omede, Paola
    Ribolla, Rossella
    Galli, Monica
    Racca, Manuela
    Zambello, Renato
    Gamberi, Barbara
    Albano, Domenico
    Versari, Annibale
    Grasso, Mariella
    Troia, Rossella
    Spadano, Tonino
    Patriarca, Francesca
    Ruggeri, Marina
    Rensi, Marco
    Pascarella, Anna
    Zucchetta, Pietro
    Tacchetti, Paola
    Fanti, Stefano
    Boccadoro, Mario
    Cavo, Michele
    Oliva, Stefania
    BLOOD, 2019, 134
12345